citing the company’s impressive performance and potential synergies from its recent acquisition of Nevro Corp. This acquisition is anticipated to influence Globus Medical’s 2025 financial ...
BTIG responded by raising its price target for Globus Medical shares to $94, maintaining a Buy rating, citing the company’s impressive performance and potential synergies from its recent acquisition ...
RBC Capital analyst Shagun Singh Chadha maintained a Buy rating on Globus Medical (GMED – Research Report) yesterday and set a price target of ...
MyChesCo on MSN9h
Globus Medical Introduces Advanced Solutions for ALIF SurgeryGlobus Medical, Inc. (NYSE: GMED) has unveiled two groundbreaking additions to its anterior lumbar interbody fusion (ALIF) ...
Medtech company Globus Medical has expanded its spine portfolio by launching its Cohere anterior lumbar interbody fusion spacer and Modulus ALIF blades. The Cohere space is the first porous ...
Globus Medical had a net margin of 4.09% and a return on equity of 10.83%. The firm had revenue of $657.29 million during the quarter, compared to analysts’ expectations of $646.19 million.
OsteoCentric Technologies has entered into a non-exclusive licensing agreement with Globus Medical. OsteoCentric’s MIS Bone Preservation Tapping Technology & Instant Interlocking Thread-form is the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback